Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety Study of GSK2190915 Formulations
NCT02224521Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fiboflapon in asthma and chronic obstructive pulmonary disease (COPD) (6 cohorts), sponsored by GSK. Primary endpoint: Composite of plasma pharmacokinetic parameters up to 36 days. Started Apr 2009; status: completed.
02
Drugs
fiboflapon
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02224521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224521.